Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration

Immune checkpoint inhibitor-based combination therapy produced high objective response for patients with hepatocellular carcinoma (HCC) and may improve clinical outcome as neoadjuvant or peri-operative therapy. This study evaluated efficacy and safety of nivolumab plus ipilimumab for patients potentially resectable HCC and explored potential predictive biomarkers for efficacy. Transcriptomics analysis was performed to investigate the biomarkers associated with the response of immune checkpoint inhibitor therapy